Research programme: MMSC1 gene - Myriad Pharmaceuticals/Schering-Plough
Latest Information Update: 10 Aug 2007
At a glance
- Originator Myriad Pharmaceuticals; Schering-Plough
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 14 Sep 1999 New profile
- 14 Sep 1999 Preclinical development for Cancer in USA (Unknown route)